MAZE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 8, 2021Investors’ Rights Agreement • July 31st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJuly 31st, 2024 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 8, 2021, by and among Maze Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the “Investors”.
MAZE THERAPEUTICS, INC. AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT December 8, 2021Investors’ Rights Agreement • June 21st, 2024 • Maze Therapeutics, Inc. • Biological products, (no disgnostic substances) • Delaware
Contract Type FiledJune 21st, 2024 Company Industry JurisdictionTHIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) is made as of December 8, 2021, by and among Maze Therapeutics, Inc., a Delaware corporation (the “Company”), each investor listed on Schedule A hereto, each of which is referred to in this Agreement as an “Investor” and collectively, the “Investors”.